|
Performance of different chemistries, compared as LOD, LOQ, efficiency, dynamic range and repeatability |
||||||||||
| No. of copies |
TaqMan®c |
LNA® |
CPT |
Lux™ |
Plexor™ |
|||||
|
|
||||||||||
| Invertase |
||||||||||
| 40000 |
24.07 (6) |
23.84 (6) |
23.15 (14) |
23.00 (6) |
24.74 (4) |
25.13 (11) |
26.76 (4) |
26.69 (2) |
24.41 (11) |
24.57 (8) |
| 4000 |
27.57 (6) |
27.31 (3) |
26.82 (9) |
26.52 (8) |
28.25 (13) |
28.21 (13) |
30.51 (11) |
30.23 (8) |
27.96 (11) |
28.13 (7) |
| 400 |
30.94 (10) |
30.68 (8) |
30.14 (19) |
29.93 (9) |
31.98 (13) |
31.91 (23) |
34.33 (15) |
34.07 (9) |
31.44 (11) |
31.61 (14) |
| 200 |
32.09 (6) |
31.62 (3) |
31.06 (8) |
30.83 (7) |
33.09 (17) |
32.16 (25) |
34.82 (12) |
34.70 (22) |
32.63 (5) |
32.51 (21) |
| 100 |
33.00 (15) |
32.63 (13) |
32.24 (18) |
31.80 (8) |
33.25 (26) |
33.75 (49) |
35.71 (39) |
35.59 (25) |
33.46 (24) |
34.00 (14) |
| 20 |
35.85 (43) |
35.28 (15) |
34.31 (19) |
34.16 (32) |
38.89 (124) |
4/5 |
3/5 |
3/5 |
35.72 (35) |
35.90 (41) |
| 4 |
4/5a |
4/5 |
2/5 |
1/5 |
4/5 |
1/5 |
2/5 |
1/5 |
4/5 |
3/5 |
| 0.4 |
1/5 a |
2/5 |
0/5 |
1/5 |
1/5 |
0/5 |
0/5 |
0/5 |
1/5 |
0/5 |
| MON 810 |
||||||||||
| 8000 |
25.23 (2)b |
24.95 (5) |
24.82 (4)b |
24.55 (3)b |
23.38 (3)b |
24.40 (3)b |
28.78 (6)b |
28.76 (6)b |
26.96 (9) |
25.42 (11) |
| 4000 |
26.00 (3) |
25.92 (2) |
25.41 (5) |
25.34 (3) |
24.11 (7) |
25.17 (3) |
29.59 (4) |
29.59 (5) |
27.94 (5) |
26.58 (16) |
| 400 |
29.41 (15) |
29.14 (8) |
28.56 (9) |
28.53 (4) |
27.42 (5) |
28.38 (4) |
32.82 (14) |
32.95 (7) |
31.37 (5) |
30.49 (15) |
| 200 |
30.57 (12) |
30.24 (10) |
29.66 (13) |
29.57 (17) |
28.67 (6) |
29.44 (2) |
34.23 (13) |
33.98 (18) |
32.53 (7) |
31.60 (14) |
| 100 |
31.54 (13) |
31.38 (24) |
30.81 (4) |
30.53 (12) |
29.63 (7) |
30.43 (8) |
35.33 (19) |
35.14 (11) |
33.71 (18) |
32.65 (19) |
| 20 |
33.94 (31) |
34.06 (47) |
33.19 (11) |
32.74 (17) |
32.46 (44) |
33.47 (26) |
38.61 (73) |
37.62 (35) |
36.25 (19) |
34.86 (28) |
| 4 |
4/5 |
36.60 (44) |
4/5 |
3/5 |
4/5 |
2/5 |
3/5 |
39.45 (50) |
4/5 |
2/5 |
| 0.4 |
2/5 |
1/5 |
0/5 |
1/5 |
1/5 |
0/5 |
1/5 |
2/5 |
0/5 |
0/5 |
|
a X/X; number of positives/number of experiments, Cv was not calculated when some of the parallels failed to amplify; binhibition was observed in these reactions as decrease in efficiency of amplification; c well established TaqMan® based amplicons were analyzed in parallel as a reference system. Values within the dynamic range are shown in bold. | ||||||||||
Buh Gašparič et al. BMC Biotechnology 2008 8:26 doi:10.1186/1472-6750-8-26 |
||||||||||